Arbutus Biopharma Stock Target Price and Analyst Consensus
| ABUS Stock | USD 2.75 0.11 4.17% |
The current analyst and expert consensus on Arbutus Biopharma is Strong Buy, with 2 strong buy opinions. The current projected Arbutus Biopharma target price consensus is 4.60 with 5 analyst opinions. The most common way Arbutus Biopharma Corp analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Arbutus Biopharma executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Arbutus Biopharma. We strongly encourage you to use your own analysis of Arbutus Biopharma Corp to validate this buy or sell advice. Arbutus Biopharma buy-or-sell recommendation module provides average expert sentiment on the projected Arbutus Biopharma Corp target price to derive its highest and lowest estimates based on its projected price volatility. Check out Macroaxis Advice on Arbutus Biopharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
Lowest Forecast 4.19 | Highest Forecast 5.11 | Target Price 4.6 |
Arbutus |
It's important to approach Arbutus Biopharma's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Arbutus Biopharma price targets
Arbutus Biopharma's stock target price is an estimate of its future price, usually made by analysts. Using Arbutus Biopharma's target price to determine if it is a suitable investment can be done through the following steps:- Look at Arbutus Biopharma's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Arbutus Biopharma's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Arbutus Biopharma Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Arbutus Biopharma is a key component of Arbutus Biopharma valuation and have some predictive power on the future returns of a Arbutus Biopharma.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arbutus Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Business Services Invested over 100 shares | |
 | Driverless Cars Invested over 60 shares | |
 | Warren Buffett Holdings Invested few shares | |
 | FinTech Invested over 40 shares | |
 | Hedge Favorites Invested over 40 shares | |
 | Chemicals Invested over 40 shares | |
Check out Macroaxis Advice on Arbutus Biopharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Arbutus Stock analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
The data published in Arbutus Biopharma's official financial statements usually reflect Arbutus Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Arbutus Biopharma Corp. For example, before you start analyzing numbers published by Arbutus accountants, it's critical to develop an understanding of what Arbutus Biopharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Arbutus Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arbutus Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Arbutus Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arbutus Biopharma Corp. Please utilize our Beneish M Score to check the likelihood of Arbutus Biopharma's management manipulating its earnings.